Nantahala Capital Management, LLC Cidara Therapeutics, Inc. Transaction History

Nantahala Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.68 - $0.97 $674,329 - $961,911	-991,661 Reduced 39.07%	1,546,745 $1.22 Million
Q3 2023 Nov 14, 2023	SELL	$0.77 - $1.16 $1.1 Million - $1.65 Million	-1,423,492 Reduced 35.93%	2,538,406 $2.39 Million
Q2 2023 Aug 14, 2023	SELL	$1.01 - $1.42 $775,412 - $1.09 Million	-767,735 Reduced 16.23%	3,961,898 $4.48 Million
Q1 2023 May 15, 2023	BUY	$0.75 - $1.98 $271,626 - $717,094	362,169 Added 8.29%	4,729,633 $6.01 Million
Q4 2022 Feb 14, 2023	SELL	$0.48 - $0.76 $92,033 - $145,720	-191,737 Reduced 4.21%	4,367,464 $3.32 Million

Q3 2022 Nov 10, 2022	SELL	$0.45 - $0.81 $116,950 - $210,510	-259,889 Reduced 5.39%	4,559,201 $2.92 Million
Q2 2022 Aug 15, 2022	SELL	$0.43 - $0.91 $58,390 - $123,570	-135,792 Reduced 2.74%	4,819,090 $2.36 Million
Q1 2022 May 13, 2022	SELL	$0.67 - $1.39 $211,435 - $438,650	-315,576 Reduced 5.99%	4,954,882 $4.13 Million
Q4 2021 Feb 14, 2022	BUY	$1.18 - $2.18 $6.22 Million - $11.5 Million	5,270,458 New	5,270,458 $6.69 Million

22.2M

2.7K

100

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $786M
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nantahala Capital Management, LLC with notifications on news.